U.S., Nov. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07251998) titled 'Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis' on Nov. 19.
Brief Summary: The purpose of this study is to compare the efficacy and safety of ICP-332 to placebo in participants with moderate-to-severe plaque psoriasis.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Plaque Psoriasis
Intervention:
DRUG: ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
DRUG: ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
DRUG: ICP-332 Tablets
ICP-332 will be administered as tablet for 12 weeks
OTHER: ICP-332 Placebo Tablets
P...